What doses and routes appear in the studies.

The short version

This page collects the doses and routes that have actually appeared in published studies — not as a guide for human use but as a record of what the literature reports. BPC-157 has been studied most often at 10 microg/kg or 10 ng/kg in rodent models, with a handful of human pilot reports using much higher absolute doses (up to 20 mg intravenously). Thymosin beta-4 in its full-length form has human Phase I data going up to 1260 mg intravenously with no dose-limiting toxicities. For the TB-500 fragment specifically, there is no published human pharmacokinetic or controlled-efficacy study.

Nothing on this page is a dosing recommendation. There is no validated dose for the combination, and the common community rationales of 'loading then maintenance' or fixed-ratio vials have no basis in any controlled trial.

A note on framing

Nothing on this page is a dose recommendation, a protocol, or a schedule for human use. Both BPC-157 and TB-500 are FDA Category 2 compounds and not approved for any human indication anywhere in the world ^[7]. What follows is a description of what doses and routes have been reported in published research, framed in the third person and attributed to the specific study that used them. Readers looking for a clinical dosing regimen will not find one here, and should not infer one by reading between the lines.

BPC-157 doses reported in research

The most common BPC-157 dose across published rodent studies is 10 μg/kg or 10 ng/kg, given intraperitoneally, intragastrically, or in drinking water ^[1][3][4][8]. These two dose levels span five orders of magnitude when expressed per kilogram — both have produced functional and histological effects in injury models, which is one of the more unusual features of the peptide's pharmacology and one of the reasons reviewers have raised replication questions.

Higher doses appear in specific contexts. The 2019 rat spinal cord compression study used a single intraperitoneal dose of 200 μg/kg or 2 μg/kg ten minutes post-injury ^[20]. The 2025 ischemia-reperfusion study used 20 μg/kg intraperitoneally ^[26]. In drinking-water protocols, the operational concentration is approximately 0.16 μg/mL or 0.16 ng/mL, with rats consuming roughly 12 mL per day ^[21].

The 2022 Frontiers in Pharmacology pharmacokinetic study evaluated BPC-157 across 20 to 500 μg/kg in rats and 6 to 150 μg/kg in beagle dogs after single intramuscular doses ^[5]. The authors proposed an extrapolated human pilot dose of 200 μg/person/day — a figure that has not been formally tested in a controlled clinical trial.

The three published human BPC-157 reports used substantially higher doses than the rodent literature. The 2021 case series used intra-articular knee injection at unspecified concentration. The 2024 interstitial cystitis pilot used 10 mg intravesicularly. The 2025 healthy-volunteer pilot used up to 20 mg as a single intravenous infusion, with reported clearance within 24 hours ^[6].

TB-500 / Tβ4 doses reported in research

Preclinical doses of TB-500 / Tβ4 in rats and mice typically range from 0.5 to 12 mg/kg intraperitoneally for stroke and dermal-wound models ^[17]. The Bock-Marquette 2004 mouse infarct study used 150 μg systemic plus a 400 ng intracardiac injection ^[9].

Human dosing has been studied most carefully with the full-length recombinant Tβ4. The 2021 NL005 Phase I in healthy Chinese volunteers used intravenous single doses of 0.05 to 25 μg/kg and multiple doses of 0.5 to 5 μg/kg/day for 10 days ^[15]. The Phase II venous-ulcer trial used a topical gel at 0.01%, 0.03%, or 0.1% applied once daily ^[12]. The Phase II severe-dry-eye trial used 0.1% ophthalmic solution dosed six times daily for 28 days ^[13]. The Phase III neurotrophic keratopathy program used the same 0.1% ophthalmic solution ^[14].

For the synthetic 7-residue TB-500 fragment specifically, the marketed Ac-LKKTETQ-OH product, no published human pharmacokinetic or controlled-efficacy study has appeared in the peer-reviewed literature. Research-peptide vendors implicitly rely on the full-length Tβ4 dataset for biological rationale. Whether the fragment is dose-equivalent to the full-length peptide on a molar or weight basis has not been formally established.

Pharmacokinetics — what we know and what we do not

The 2022 Frontiers in Pharmacology pharmacokinetic study of BPC-157 in Sprague-Dawley rats and beagle dogs reported a plasma half-life under 30 minutes after intramuscular dosing, with a Tmax of approximately 3 minutes in rats and 6 to 9 minutes in dogs ^[5]. Intramuscular bioavailability was 14 to 19 percent in rats and 45 to 51 percent in dogs. Metabolism produced six small peptide fragments terminating in free amino acids (notably proline), with urinary and biliary elimination. No published human pharmacokinetic dataset for BPC-157 exists outside the 2025 single-arm IV pilot, which reported clearance within 24 hours but did not formally model PK parameters ^[6].

For full-length Tβ4, the 2021 NL005 Phase I reported dose-proportional pharmacokinetics with half-life increasing at higher doses; reported terminal half-life in healthy human volunteers was on the order of 1 to 2 hours at therapeutic doses ^[15]. The 7-mer TB-500 fragment has not been the subject of a published human PK study; its half-life is likely shorter than full-length Tβ4 because it lacks the N- and C-terminal extensions that contribute to plasma stability ^[22].

BPC-157 is stable in gastric juice — resistant to acid-mediated proteolysis — which is why peroral drinking-water administration is used routinely in rodent studies; the three consecutive prolines at positions 3-5 of the GEPPPGKPADDAGLV sequence are thought to drive this stability ^[19]. The TB-500 fragment is N-acetylated (Ac-LKKTETQ-OH) to slow exopeptidase degradation ^[22].

Routes that have appeared in research

BPC-157 has been studied across a wide range of routes in animal models: intraperitoneal injection (the most common), intragastric gavage, peroral drinking water, subcutaneous injection, intramuscular injection, topical cream (at approximately 1 μg/g), intravenous infusion (the 2025 human pilot), intra-articular injection (the 2021 human knee case series), and intravesicular instillation (the 2024 interstitial cystitis pilot) ^{[1][5][6][8][20][21]}.

TB-500 / Tβ4 has been studied via intraperitoneal injection, subcutaneous injection, intravenous infusion (human Phase I and Phase II programs), intracardiac injection (preclinical only), topical ophthalmic application (Phase II and Phase III ocular trials), and topical dermal application (Phase II wound trials) ^{[9][12][13][14][15][17]}.

No published controlled study of the BPC-157 + TB-500 combination has appeared in a peer-reviewed journal, so no combination route has been formally validated ^[6][16].